Innate Pharma (NASDAQ: IPHA) has entered into a strategic partnership with Sobi (#SOBI) to license lacutamab, an investigational therapy being developed for T-cell lymphoma. The agreement gives Sobi rights to further develop and commercialize lacutamab, strengthening Innate Pharma's strategy of advancing its oncology pipeline through strategic partnerships. Sector: Biotechnology / Oncology Key Highlights 🤝 Innate Pharma partnered with Sobi 💊 Lacutamab licensed for development in T-cell lymphoma 🧬 Expands Sobi's hematology and oncology portfolio 🌍 Partnership supports potential future development and commercialization 🚀 Strengthens Innate Pharma's strategy of leveraging partnerships to advance its pipeline Why It Matters The partnership gives lacutamab access to Sobi's development and commercial capabilities while providing Innate Pharma with a strategic path to advance its oncology asset toward broader patient access. Read More: https://www.thinksabio.com/reports/isr/IPHA